Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

GLP-1 receptor agonists mimic the actions of GLP-1 and are used to manage type 2 diabetes and help with weight loss. In recent times, antidiabetic GLP-1 receptor agonists have been misused widely for weight loss. This review article focuses on some serious side effects of GLP-1 receptor agonists, notified by different regulatory agencies. We searched the literature in online databases such as Medline/Pubmed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of Science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of GLP-1 receptor agonists. Various pharmacovigilance analyses and notifications from different regulatory agencies have documented the occurrence of suicidal thoughts and self-injurious behavior associated with the use of GLP-1 receptor agonists. Healthcare professionals should be aware of GLP-1 receptor agonists-associated suicidal thoughts and self-injurious behavior. Patients should not misuse/abuse antidiabetic GLP-1 receptor agonists and should consult their physician before using any GLP-1 receptor agonists for weight loss.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863301925240507044637
2024-05-17
2025-09-01

  • From This Site

    /content/journals/cds/10.2174/0115748863301925240507044637
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MüllerT.D. FinanB. BloomS.R. Glucagon-like peptide 1 (GLP-1).Mol. Metab.2019307213010.1016/j.molmet.2019.09.010 31767182
     [Google Scholar]
  2. GentilellaR. PechtnerV. CorcosA. ConsoliA. Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: Are they all the same?Diabetes Metab. Res. Rev.2019351e307010.1002/dmrr.3070 30156747
     [Google Scholar]
  3. ShaeferC.F.Jr KushnerP. AguilarR. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists.Postgrad. Med.2015127881882610.1080/00325481.2015.1090295 26371721
     [Google Scholar]
  4. RyanD. AcostaA. GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Obesity 20152361119112910.1002/oby.21107 25959380
     [Google Scholar]
  5. ArdJ. FitchA. FruhS. HermanL. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists.Adv. Ther.20213862821283910.1007/s12325‑021‑01710‑0 33977495
     [Google Scholar]
  6. FilippatosT.D. PanagiotopoulouT.V. ElisafM.S. Adverse effects of GLP-1 receptor agonists.Rev. Diabet. Stud.2014113-420223010.1900/RDS.2014.11.202 26177483
     [Google Scholar]
  7. SodhiM. RezaeianzadehR. KezouhA. EtminanM. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.JAMA2023330181795179710.1001/jama.2023.19574 37796527
     [Google Scholar]
  8. RespoautR. TerhuneC. Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts2023Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-other-weight-loss-drugs-scrutinized-over-reports-suicidal-thoughts-2023-09-28/ Accessed on Dec 13, 2023.
     [Google Scholar]
  9. EMA statement on ongoing review of GLP-1 receptor agonists2023Available from: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists Accessed on December 13, 2023
  10. CohenD. GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm.BMJ2023383290610.1136/bmj.p2906 38084503
     [Google Scholar]
  11. HSA is assessing the potential risk of suicidal thoughts and selfharm with glucagon-like peptide-1 receptor agonists (GLP-1 RA).2023Available from: https://www.hsa.gov.sg/announcements/safety-alert/hsa-is-assessing-the-potential-risk-of-suicidal-thoughts-and-self-harm-with-glucagon-like-peptide-1-receptor-agonists-(glp-1-ra) Accessed on December 14, 2023.
  12. GrassaJ.L. Health Canada assessing popular diabetes, weight-loss drugs like Ozempic for suicide risk2023Available from: https://www.cbc.ca/news/health/health-canada-review-diabetes-weight-loss-1.6921759 Accessed on December 14, 2023.
     [Google Scholar]
  13. McIntyreR.S. MansurR.B. RosenblatJ.D. KwanA.T.H. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).Expert Opin. Drug Saf.2024231475510.1080/14740338.2023.2295397 38087976
     [Google Scholar]
  14. ChenC. ZhouR. FuF. XiaoJ. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: A real-world pharmacovigilance analysis.Eur. Psychiatry2023661e9910.1192/j.eurpsy.2023.2474 38031404
     [Google Scholar]
  15. TobaiqyM. ElkoutH. Analysis of psychiatric adverse events for semaglutide, liraglutide, and tirzepatide reported to the eudravigilance database.Research Square202310.21203/rs.3.rs‑3419258/v1
     [Google Scholar]
  16. WangW. VolkowN.D. BergerN.A. DavisP.B. KaelberD.C. XuR. Association of semaglutide with risk of suicidal ideation in a real-world cohort.Nat. Med.202430116817610.1038/s41591‑023‑02672‑2 38182782
     [Google Scholar]
  17. VerovnikB. VovkA. Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.Diabetes Obes. Metab.202426278278410.1111/dom.15363 37945545
     [Google Scholar]
  18. United States Food and Drug Administration. Drug Safety and Availability. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity2024Available from: https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type Accessed on Jan 27, 2024.
  19. RuggieroR. MascoloA. SpezzaferriA. Glucagon-like peptide-1 receptor agonists and suicidal ideation: Analysis of real-word data collected in the european pharmacovigilance database.Pharmaceuticals202417214710.3390/ph17020147 38399362
     [Google Scholar]
  20. ZhouJ. ZhengY. XuB. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: A pharmacovigilance study based on the FDA Adverse Event Reporting System database.BMC Med.20242216510.1186/s12916‑024‑03274‑6 38355513
     [Google Scholar]
  21. NassarM. MisraA. BloomgardenZ. Impact of treatment with GLP‐1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database.J. Diabetes2024163e1354710.1111/1753‑0407.13547 38501220
     [Google Scholar]
  22. GuirguisA. ChiappiniS. PapantiP.G.D. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.Eur. Neuropsychopharmacol.202482829110.1016/j.euroneuro.2024.02.003 38508100
     [Google Scholar]
  23. KimJ.H. KimJ.Y. LeeS. Environmental risk factors, protective factors, and biomarkers for postpartum depressive symptoms: An umbrella review.Neurosci. Biobehav. Rev.202214010476110.1016/j.neubiorev.2022.104761 35803397
     [Google Scholar]
  24. AbdElmageed RM, Mohammed Hussein SM. Risk of depression and suicide in diabetic patients.Cureus2022141e20860 35145767
     [Google Scholar]
  25. Ninla-aesongP. PuangsriP. KietdumrongwongP. JongkrijakH. NoiphaK. Being overweight and obese increases suicide risk, the severity of depression, and the inflammatory response in adolescents with major depressive disorders.Front. Immunol.202314119777510.3389/fimmu.2023.1197775 38022570
     [Google Scholar]
  26. ChiappiniS. Vickers-SmithR. HarrisD. Is there a risk for semaglutide misuse? Focus on the food and drug administration’s FDA adverse events reporting system (FAERS) pharmacovigilance dataset.Pharmaceuticals202316799410.3390/ph16070994 37513906
     [Google Scholar]
/content/journals/cds/10.2174/0115748863301925240507044637
Loading
Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon-Like Peptide-1 Receptor Agonists - A Review
Curr Drug Saf 20, 253 (2025); https://doi.org/10.2174/0115748863301925240507044637
/content/journals/cds/10.2174/0115748863301925240507044637
/content/journals/cds/10.2174/0115748863301925240507044637
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): depression; dulaglutide; GLP-1 receptor agonists; self-injurious behavior; semaglutide; suicidal thoughts; tirzepatide

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test